As TMB and MSI seem to be the key factors in determining whether to undertake an immune checkpoint therapy or not, we have investigated and compared the correlation between NCAPG2 expression and TMB as well as MSI in a pan-cancer. This evidence concerns the gene NCAPG2 and cancer.